Commissioner of health directed to study and report on activities to support innovations in cell and gene therapy to treat rare diseases, report required, and money appropriated.
Author added
Email me when HF 4064 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HF 4064. By continuing you agree to the Terms and Privacy Policy.
Summary
The bill directs Minnesota’s commissioner of health, in partnership with the University of Minnesota and other stakeholders, to conduct a comprehensive study of the state’s capacity and strategies for cell and gene therapies that treat rare diseases. The commissioner must deliver a report with findings, recommendations, and potential funding opportunities by Jan 1 2028, and post it on the Department of Health website. A one‑time appropriation from the general fund for FY 2027 funds the study, and the money expires June 30 2028.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HF 4064
3 free questions a day, no accountHearings
- Health Finance and PolicyHealth Finance and Policy · Mar 23, 2026
History
- Author added Torkelson
- Introduction and first reading, referred to Health Finance and Policy
Sponsors
- Reyer · sponsor
- Backer
- Berg
- Bierman
- Freiberg
- Hollins
- Mahamoud
- Nadeau
- Torkelson
- Virnig
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HF 4064 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HF 4064 freeOr ask your AI assistant about HF 4064 directly:
Add to Claude, ChatGPT or Cursor